<DOC>
	<DOCNO>NCT01555892</DOCNO>
	<brief_summary>Subjects type lymph gland disease call Hodgkin non-Hodgkin Lymphoma T/NK-lymphoproliferative disease severe chronic active Epstein Barr Virus ( CAEBV ) come back , risk come back , go away treatment , include best treatment know diseases . Some patient Lymphoma T/NK-lymphoproliferative disease CAEBV show sign virus call Epstein Barr virus ( EBV ) cause mononucleosis glandular fever ( `` mono '' `` kiss disease '' ) time diagnosis . EBV find cancer cell half patient HD NHL , suggest may play role cause Lymphoma . The cancer cell ( lymphoma ) immune system cell ( CAEBV ) infect EBV able hide body 's immune system escape destruction . We want see special white blood cell , call GRALE T cell , train kill EBV infected cell survive blood affect tumor . We use sort therapy treat different type cancer occur bone marrow solid organ transplant call post transplant lymphoma . In type cancer tumor cell 9 protein make EBV surface . We grow T cell lab recognize 9 protein able successfully prevent treat post transplant lymphoma . However , HD NHL , T/NK-lymphoproliferative disease , CAEBV , tumor cell B cell express 4 EBV protein . In previous study , make T cell recognize 9 protein give patient HD . Some patient partial response therapy patient complete response . We follow study make T cell recognize 2 EBV protein see patient lymphoma , T/NK-lymphoproliferative disease CAEBV . Those protein call LMP-1 LMP-2 . The cell call LMP-specific cytotoxic T-Lymphocytes ( CTLs ) . We treat 45 people study . About 63 % patient disease time get cell response include patient complete response . This study expand result try make T cell lab simpler fast way . We also make T cell still see LMP protein also 2 EBV protein call EBNA-1 BARF . These cell call GRALE T cell . These GRALE CTLs investigational product approve FDA . The purpose study find large safe dose LMP-specific cytotoxic GRALE T cell create use new manufacturing technique . We learn side effect see whether therapy might help patient HD NHL EBV associate T/NK-lymphoproliferative disease CAEBV .</brief_summary>
	<brief_title>Cytotoxic T-Lymphocytes EBV-positive Lymphoma , GRALE</brief_title>
	<detailed_description>Subjects ( syngeneic donor ) give blood investigator make LMP/BARF1/EBNA-1 ( GRALE ) CTLs lab . These cell grow frozen subject . Patients start low dose ( 1 3 different level ) GRALE T cell . Once dose schedule prove safe , next group patient start high dose . This process continue 3 dose level study . If side effect severe , dose lower GRALE T cell injection stop . The GRALE T cell thaw injected subject 2-10 minute . Initially , two dos GRALE T cell give 2 week apart . If 2nd infusion reduction size lymphoma CT MRI scan assess radiologist , subject receive additional dos GRALE T cell wish ( 6 time ) . Follow test collect like 1st infusion . All treatment give Center Cell Gene Therapy Texas Children 's Hospital Houston Methodist Hospital . We follow subject injection . They either see clinic subject contact research nurse yearly 5 year . If receive additional dos GRALE T cell describe , follow 5 year last dose GRALE T-cells .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<criteria>Inclusion Criteria time Procurement 1 . Any patient , regardless age sex , EBVpositive Hodgkin 's nonHodgkin 's Lymphoma , ( regardless histological subtype ) EBV ( associate ) T/NKlymphoproliferative disease Severe Chronic Active EBV ( CAEBV ) may subsequently eligible treatment component 2 . EBV positive tumor ( pending time ) 3 . Weighs least 12kg 4 . Informed consent explain , understood sign patient/guardian . Patient/guardian give copy inform consent . Inclusion Criteria time Infusion 1 . Any patient , regardless age sex , EBVpositive Hodgkin 's nonHodgkin 's Lymphoma ( regardless histologic subtype ) , EBV ( associate ) T/NKlymphoproliferative disease Severe Chronic Active EBV ( CAEBV ) In second subsequent relapse ( first relapse active disease immunosuppressive chemotherapy contraindicate multiply relapsed patient remission high risk relapse ) OR patient primary disease first remission immunosuppressive chemotherapy contraindicate , e.g . patient develop Hodgkin disease solid organ transplantation Lymphoma second malignancy e.g . Richter 's transformation CLL . ( Group A ) OR In remission minimal residual disease status autologous syngeneic SCT . ( Group B ) 2 . EBV positive tumor 3 . Patients life expectancy great equal 6 week . 4 . Patients bilirubin less equal 3x upper limit normal , AST le equal 5x upper limit normal , Hgb &gt; 8.0 ( may transfuse value ) . 5 . Patients creatinine less equal 2x upper limit normal age 6 . Pulse oximetry &gt; 90 % room air 7 . Patients investigational therapy 4 week prior entry study . 8 . Patients Karnofsky/Lansky score great equal 50 9 . Sexually active patient must willing utilize one effective birth control method study 6 month study conclude . The male partner use condom . 10 . Informed consent explain , understood sign patient/guardian . Patient/guardian give copy inform consent . CAEBV define patient high EBV viral load plasma PBMC ( &gt; 4000 genome per ug PBMC DNA ) and/or biopsy tissue positive EBV Patients relapse refractory lymphoma eligible stem cell transplant treat study alternative transplant . Exclusion Criteria Time Procurement 1 . Active infection HIV , HTLV , HBV , HCV ( pending time ) Exclusion Criteria Time Infusion 1 . Pregnant lactate 2 . Severe intercurrent infection . 3 . Current use systemic corticosteroid &gt; 0.5 mg/kg/day</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>EBV</keyword>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Lymphoma Relapse</keyword>
	<keyword>Autologous Syngeneic Stem Cell Transplant</keyword>
	<keyword>T/NK-lymphoproliferative disease</keyword>
	<keyword>LMP</keyword>
	<keyword>BARF1</keyword>
	<keyword>EBNA1</keyword>
</DOC>